TN2009000241A1 - Nutritional supplement composition for treatment of ocular diseases - Google Patents

Nutritional supplement composition for treatment of ocular diseases

Info

Publication number: TN2009000241A1
Authority: TN; Tunisia
Prior art keywords: supplement composition; treatment; nutritional supplement; ocular diseases; macular degeneration
Prior art date: 2006-12-15

Application number

TNP2009000241A

Other languages

English (en)

Inventor

Georg Ludwig Kis

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-15

Filing date

2009-06-12

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000241(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-12 Application filed by Novartis Ag filed Critical Novartis Ag

2010-10-18 Publication of TN2009000241A1 publication Critical patent/TN2009000241A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Inorganic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

TNP2009000241A 2006-12-15 2009-06-12 Nutritional supplement composition for treatment of ocular diseases TN2009000241A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06126261A EP1932521A1 (fr)	2006-12-15	2006-12-15	Composition de supplément nutritionnel pour le traitement des maladies oculaires
PCT/EP2007/063908 WO2008071775A1 (fr)	2006-12-15	2007-12-13	Composition de supplément nutritionnel pour le traitement de maladies oculaires

Publications (1)

Publication Number	Publication Date
TN2009000241A1 true TN2009000241A1 (en)	2010-10-18

Family

ID=38024441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000241A TN2009000241A1 (en)	2006-12-15	2009-06-12	Nutritional supplement composition for treatment of ocular diseases

Country Status (22)

Country	Link
US (1)	US20100028459A1 (fr)
EP (2)	EP1932521A1 (fr)
JP (1)	JP2010513248A (fr)
KR (1)	KR20090089473A (fr)
CN (1)	CN101557807A (fr)
AR (1)	AR064332A1 (fr)
AU (1)	AU2007331432A1 (fr)
BR (1)	BRPI0720046A2 (fr)
CA (1)	CA2672013A1 (fr)
CL (1)	CL2007003630A1 (fr)
CO (1)	CO6220929A2 (fr)
EC (1)	ECSP099516A (fr)
GT (1)	GT200900161A (fr)
MA (1)	MA30994B1 (fr)
MX (1)	MX2009006306A (fr)
NO (1)	NO20092633L (fr)
PE (1)	PE20081580A1 (fr)
RU (1)	RU2009126735A (fr)
TN (1)	TN2009000241A1 (fr)
TW (1)	TW200843725A (fr)
WO (1)	WO2008071775A1 (fr)
ZA (1)	ZA200903862B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8389504B2 (en) *	2008-05-08	2013-03-05	Mead Johnson Nutrition Company	Prenatal dietary supplement
WO2010074940A1 (fr) *	2008-12-23	2010-07-01	Alcon Research, Ltd.	Compositions et compléments nutritionnels améliorant la santé oculaire et réduisant la réponse inflammatoire de l'oeil
US20110021465A1 (en) *	2009-07-23	2011-01-27	U.S. Nutraceuticals, Llc D/B/A Valensa International	Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US20130295171A1 (en)	2009-07-23	2013-11-07	U.S NUTRACEUTICALS, LLC d/b/a Valensa International	Krill oil and reacted astaxanthin composition and associated method
US20110237548A1 (en) *	2009-07-23	2011-09-29	U.S. Nutraceuticals, Llc D/B/A Valensa International	Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
US20130011469A1 (en)	2009-07-23	2013-01-10	U.S. Nutraceuticals, Llc D/B/A Valensa International	Krill oil and carotenoid composition, associated method and delivery system
ES2832734T3 (es) *	2011-07-07	2021-06-11	Howard Foundation Holdings Ltd	Mejoras en el rendimiento visual o relacionadas con este
US9381183B2 (en)	2012-07-18	2016-07-05	Physicians Recommended Nutriceuticals, Llc	Methods for improving the quality of the meibum composition of meibomian glands
US20210121430A1 (en)	2011-07-18	2021-04-29	Prn Physician Recommended Nutriceuticals, Llc	Omega-3 fatty acid supplementation for use in treating dry eye
US10709680B2 (en)	2011-07-18	2020-07-14	Physicians Recommended Nutriceuticals, Llc	Methods for treating dry eye
US9115078B2 (en)	2011-07-18	2015-08-25	Physicians Recommended Nutriceuticals, Llc	Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
SI2755647T1 (sl) *	2011-09-12	2015-11-30	Georgiou, Tassos Ophthalos Eye And Laset Centre	Uporaba omega maščobnih kislin za zdravljenje bolezni
CN102538980A (zh) *	2012-01-12	2012-07-04	杭州美盛红外光电技术有限公司	热像装置和热像拍摄方法
JP2016185939A (ja) *	2015-03-27	2016-10-27	ロート製薬株式会社	経口組成物
JP2016190829A (ja) *	2015-03-31	2016-11-10	ウィルファーム株式会社	活性型ｄｈａを含む製剤、強化食品、サプリメント並びに化粧品
JP6056114B2 (ja) *	2015-05-30	2017-01-11	富田製薬株式会社	油状物質含有粉末組成物
CN108208804A (zh) *	2018-01-05	2018-06-29	美博迪尔（北京）生物科技有限公司	一种缓解眼睛干涩、抵御蓝光损伤及保护眼底的组合物及其制备方法
CN108096288A (zh) *	2018-01-16	2018-06-01	南京圣诺生物科技实业有限公司	护眼片及其制备方法和应用
MY207914A (en) *	2018-11-27	2025-03-27	Novaliq Gmbh	Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
JP2023533633A (ja) *	2020-03-11	2023-08-04	ボシュ＋ロムアイルランドリミテッド	超長鎖脂肪酸を含む眼の健康のための組成物および方法
WO2025151943A1 (fr) *	2024-01-18	2025-07-24	Moro Peres Nemecio	Complément alimentaire particulièrement indiqué pour combattre la dégénérescence maculaire, capsule comprenant ledit complément alimentaire et utilisation de celui-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003003981A2 (fr) *	2001-07-05	2003-01-16	Vital Basics, Inc.	Compositions permettant d'ameliorer la performance mentale
US6649195B1 (en) *	2002-07-11	2003-11-18	Vitacost.Com, Inc.	Eyesight enhanced maintenance composition
WO2005027950A1 (fr) *	2003-09-12	2005-03-31	Ray And Terry's Health Products, Inc.	Complement nutritionnel pour l'oeil
US7887847B2 (en) *	2004-05-08	2011-02-15	Paul Jr Edward L	Nutritional supplement for treatment of ocular diseases
DE202005012984U1 (de) *	2005-08-17	2005-11-24	W & B Pharmamarken Gmbh	Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen
KR20080078066A (ko) *	2005-12-20	2008-08-26	알콘 리서치, 리미티드	황반변성 진행 억제 및 눈의 건강 증진을 위한 조성물 및방법

2006
- 2006-12-15 EP EP06126261A patent/EP1932521A1/fr not_active Ceased
2007
- 2007-12-13 JP JP2009540779A patent/JP2010513248A/ja active Pending
- 2007-12-13 EP EP07857555A patent/EP2094252A1/fr not_active Withdrawn
- 2007-12-13 CN CNA2007800457551A patent/CN101557807A/zh active Pending
- 2007-12-13 US US12/518,508 patent/US20100028459A1/en not_active Abandoned
- 2007-12-13 MX MX2009006306A patent/MX2009006306A/es not_active Application Discontinuation
- 2007-12-13 AU AU2007331432A patent/AU2007331432A1/en not_active Abandoned
- 2007-12-13 BR BRPI0720046-3A2A patent/BRPI0720046A2/pt not_active Application Discontinuation
- 2007-12-13 RU RU2009126735/15A patent/RU2009126735A/ru not_active Application Discontinuation
- 2007-12-13 CA CA002672013A patent/CA2672013A1/fr not_active Abandoned
- 2007-12-13 AR ARP070105598A patent/AR064332A1/es unknown
- 2007-12-13 WO PCT/EP2007/063908 patent/WO2008071775A1/fr not_active Ceased
- 2007-12-13 PE PE2007001783A patent/PE20081580A1/es not_active Application Discontinuation
- 2007-12-13 KR KR1020097014635A patent/KR20090089473A/ko not_active Withdrawn
- 2007-12-14 TW TW096148104A patent/TW200843725A/zh unknown
- 2007-12-14 CL CL200703630A patent/CL2007003630A1/es unknown
2009
- 2009-06-03 ZA ZA200903862A patent/ZA200903862B/xx unknown
- 2009-06-12 GT GT200900161A patent/GT200900161A/es unknown
- 2009-06-12 TN TNP2009000241A patent/TN2009000241A1/fr unknown
- 2009-06-15 MA MA31993A patent/MA30994B1/fr unknown
- 2009-07-10 NO NO20092633A patent/NO20092633L/no not_active Application Discontinuation
- 2009-07-15 CO CO09073309A patent/CO6220929A2/es not_active Application Discontinuation
- 2009-07-15 EC EC2009009516A patent/ECSP099516A/es unknown

Also Published As

Publication number	Publication date
MX2009006306A (es)	2009-06-23
ECSP099516A (es)	2009-08-28
TW200843725A (en)	2008-11-16
CA2672013A1 (fr)	2008-06-19
BRPI0720046A2 (pt)	2013-12-24
NO20092633L (no)	2009-07-10
ZA200903862B (en)	2010-05-26
AU2007331432A1 (en)	2008-06-19
WO2008071775A1 (fr)	2008-06-19
AR064332A1 (es)	2009-04-01
US20100028459A1 (en)	2010-02-04
EP2094252A1 (fr)	2009-09-02
CL2007003630A1 (es)	2008-08-08
CO6220929A2 (es)	2010-11-19
PE20081580A1 (es)	2009-01-01
RU2009126735A (ru)	2011-01-20
EP1932521A1 (fr)	2008-06-18
CN101557807A (zh)	2009-10-14
MA30994B1 (fr)	2009-12-01
GT200900161A (es)	2009-11-30
KR20090089473A (ko)	2009-08-21
JP2010513248A (ja)	2010-04-30

Publication	Publication Date	Title
TN2009000241A1 (en)	2010-10-18	Nutritional supplement composition for treatment of ocular diseases
MX2009006342A (es)	2009-08-07	Composicion de complemento alimenticio para tratamiento de enfermedades oculares.
AR034220A1 (es)	2004-02-04	Complemento nutricional para tratar la degeneracion macular
AU2012223124A8 (en)	2013-11-07	Multi-band color vision filters and method by LP-optimization
MY151018A (en)	2014-03-31	Use of nutritional compositions for preventing disorders
GB201305581D0 (en)	2013-05-08	Composition and method of manufacture
IL183284A0 (en)	2007-09-20	Methods and compositions for treating ocular disorders
WO2007098122A3 (fr)	2008-07-03	Méthodes pour traiter une dégénérescence maculaire et des troubles apparentés de l'œil
MX2011013060A (es)	2012-02-28	Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
GEP20084520B (en)	2008-10-27	Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
MY176679A (en)	2020-08-19	Use of nutritional compositions for preventing disorders
AU2008313418A8 (en)	2013-10-31	Composition for regulating lipid metabolism
WO2007076416A3 (fr)	2007-08-16	Composition et procedes d’inhibition de la progression d’une degeneration maculaire et promotion d’une vision saine
EA201301277A1 (ru)	2014-04-30	Композиции и способы лечения заболеваний сетчатки
NZ778131A (en)	2023-03-31	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2008094825A3 (fr)	2008-10-02	Compositions et procédés destinés à maintenir, renforcer, améliorer ou favoriser la santé des yeux
MX2009012645A (es)	2010-03-08	Formulaciones y metodos para tratar el ojo seco.
TW200714277A (en)	2007-04-16	Methods and compositions for altering cell fuction
MY149606A (en)	2013-09-13	Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
MY153738A (en)	2015-03-13	Sulphur-linked compounds for treating ophthalmic diseases and disorders.
WO2012080497A3 (fr)	2012-08-23	Procédés de traitement et de prévention de maladies oculaires
EA200800291A1 (ru)	2008-06-30	Способы и композиции для лечения офтальмологических состояний
WO2008070169A3 (fr)	2008-11-06	Utilisation d'orotate de carboxyamidotriazole (cai) dans la dégénérescence maculaire
MX338323B (es)	2016-04-12	Formulacion topica oftalmica de peptidos.
ECSP13012799A (es)	2013-10-31	Uso de composiciones nutricionales que incluyen lactoferrinas para mejorar la resistencia a enfermedades y condiciones